Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.60
+0.23 (1.86%)
At close: May 22, 2026, 4:00 PM EDT
12.58
-0.02 (-0.16%)
Pre-market: May 26, 2026, 4:38 AM EDT

Intellia Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,7611,0461,1902,8353,0398,807
Market Cap Growth
105.26%-12.10%-58.04%-6.70%-65.49%144.43%
Enterprise Value
1,324662.66778.12,0201,9608,123
Last Close Price
12.608.9911.6630.4934.89118.24
PS Ratio
26.6415.4520.5678.1758.31266.46
PB Ratio
2.441.561.362.702.468.47
P/TBV Ratio
2.271.451.322.582.178.06
EV/Sales Ratio
20.039.7913.4455.6937.61245.77
Debt / Equity Ratio
0.100.100.220.090.090.06
Net Debt / Equity Ratio
-0.48-0.53-0.45-0.76-0.86-0.65
Net Debt / EBITDA Ratio
0.720.830.751.572.362.59
Net Debt / FCF Ratio
0.810.901.101.953.062.84
Asset Turnover
0.080.070.050.030.040.03
Quick Ratio
5.044.425.508.239.455.97
Current Ratio
6.105.085.778.679.616.11
Return on Equity (ROE)
-61.07%-53.48%-54.00%-42.10%-41.67%-34.18%
Return on Assets (ROA)
-52.56%-43.38%-42.88%-36.53%-32.56%-27.18%
Return on Invested Capital (ROIC)
-129.81%-104.79%-128.15%-179.00%-121.48%-99.99%
Return on Capital Employed (ROCE)
-59.23%-48.50%-47.16%-39.96%-35.76%-30.08%
Buyback Yield / Dilution
-11.18%-9.64%-11.35%-15.33%-8.57%-26.63%
Total Shareholder Return
-11.18%-9.64%-11.35%-15.33%-8.57%-26.63%
Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q